Moderna (MRNA) closed at $63.94 in the latest trading session, marking a -0.31% move from the prior day. This change lagged the S&P 500's 0.25% gain on the day. At the same time, the Dow added 0.2%, ...

RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

According to GlobalData, while the majority of the 22 vaccine candidates currently in development rely on traditional ...

A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

Discover Curevac NV's groundbreaking patent for an mRNA-based vaccine targeting prostate cancer. Learn how it stimulates immune responses against multiple antigens.

Modernas new cancer vaccine, mRNA-4359, shows promising results in early clinical trials. Utilizing mRNA technology, similar ...

Discover Arcturus Therapeutics' groundbreaking patent for mRNA constructs targeting cystic fibrosis. Learn how innovative lipid formulations may transform treatment options.

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Moderna (MRNA – Research Report), with a price ...